Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · July 12, 2023

Triple Hormone Receptor Agonist Retatrutide for the Treatment of Obesity

The New England Journal of Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

The New England Journal of Medicine
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
N. Engl. J. Med 2023 Jun 26;[EPub Ahead of Print], AM Jastreboff, LM Kaplan, JP Frías, Q Wu, Y Du, S Gurbuz, T Coskun, A Haupt, Z Milicevic, ML Hartman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading